CINECA IRIS Institutional Research Information System

SANGIOLO, Dario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.920
EU - Europa 3.353
AS - Asia 2.329
SA - Sud America 88
OC - Oceania 37
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 9
Totale 11.771
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.566
CN - Cina 1.046
IT - Italia 1.033
DE - Germania 605
SG - Singapore 466
GB - Regno Unito 342
CA - Canada 330
IE - Irlanda 295
SE - Svezia 257
TR - Turchia 197
FR - Francia 155
FI - Finlandia 146
VN - Vietnam 110
JP - Giappone 109
UA - Ucraina 93
PL - Polonia 91
KR - Corea 88
IN - India 69
BR - Brasile 58
ES - Italia 58
ID - Indonesia 54
NL - Olanda 52
HK - Hong Kong 50
TW - Taiwan 49
AT - Austria 40
BE - Belgio 32
AU - Australia 31
CH - Svizzera 25
NO - Norvegia 24
TH - Thailandia 24
RU - Federazione Russa 23
MX - Messico 19
IR - Iran 16
PT - Portogallo 15
SN - Senegal 14
AR - Argentina 12
GR - Grecia 11
IL - Israele 11
RO - Romania 11
SA - Arabia Saudita 11
HR - Croazia 9
EG - Egitto 7
EU - Europa 7
CO - Colombia 6
HU - Ungheria 6
NZ - Nuova Zelanda 6
BY - Bielorussia 5
LT - Lituania 5
UZ - Uzbekistan 5
VE - Venezuela 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
PK - Pakistan 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
BA - Bosnia-Erzegovina 3
CL - Cile 3
KE - Kenya 3
MK - Macedonia 3
MY - Malesia 3
NG - Nigeria 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MA - Marocco 2
PE - Perù 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BT - Bhutan 1
EC - Ecuador 1
EE - Estonia 1
GA - Gabon 1
IQ - Iraq 1
JO - Giordania 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
OM - Oman 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
SV - El Salvador 1
TN - Tunisia 1
UY - Uruguay 1
Totale 11.771
Salva come PNG Salva come JPEG
Città #
Chandler 523
Fairfield 406
Beijing 371
Houston 342
Singapore 338
Munich 331
Dublin 291
Mcallen 278
Montréal 273
Ashburn 264
Santa Clara 263
Torino 201
Woodbridge 198
Ann Arbor 182
Turin 173
Seattle 170
Wilmington 146
Jacksonville 135
Nyköping 121
Cambridge 116
Shanghai 106
Pisa 100
Columbus 95
Redwood City 94
New York 92
Medford 89
Dearborn 79
Villeurbanne 78
Princeton 77
Warsaw 72
Milan 69
Guangzhou 64
Dong Ket 55
Jakarta 53
Nanjing 51
Helsinki 45
Fremont 40
San Diego 38
Taipei 37
Boston 36
Hangzhou 32
Los Angeles 28
Silver Spring 25
Nuremberg 24
Wuhan 24
Xian 24
Washington 23
Chicago 21
Hong Kong 21
Boardman 20
Vienna 20
Seoul 19
Pune 18
Zhengzhou 18
Brussels 17
Tokyo 17
Toronto 17
Chengdu 16
Hebei 16
Hefei 16
Dresden 15
Rome 15
Changsha 14
Kunming 14
Phoenix 14
Upper Marlboro 14
Istanbul 13
Stavanger 13
Dallas 12
Madrid 12
Tianjin 12
Florence 11
Norwalk 11
Paris 11
San Mateo 11
Berlin 10
Carrara 10
Changchun 10
Fuzhou 10
Jinan 10
Bari 9
Bologna 9
Chongqing 9
Detroit 9
Falls Church 9
Lappeenranta 9
Mountain View 9
Mumbai 9
Naples 9
Ottawa 9
Ankara 8
Bangkok 8
Birmingham 8
Freiburg im Breisgau 8
Heidelberg 8
London 8
San Francisco 8
Barcelona 7
Buenos Aires 7
Central 7
Totale 7.317
Salva come PNG Salva come JPEG
Nome #
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. 1.398
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial 1.052
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? 525
Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy 436
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 379
Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells 328
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. 248
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 235
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 219
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models 212
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 207
Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 186
Adoptive immunotherapy against ovarian cancer 177
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma 174
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. 165
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 164
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 159
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy 152
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives 150
Pazopanib and trametinib as a synergistic strategy against osteosarcoma: Preclinical activity and molecular insights 149
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. 146
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. 141
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives 138
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 137
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 131
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways 130
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 129
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 128
Next generation immune-checkpoints for cancer therapy 121
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination 112
Recent advances in the development of breast cancer vaccines. 111
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 110
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 110
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 104
Recruitment, infiltration and cytotoxicity of hla-independent killer lymphocytes in three-dimensional melanoma models 104
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 99
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours 98
Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich Syndrome gene 97
Treatment of metastatic melanoma: a multidisciplinary approach 97
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. 94
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 94
Adoptive immunotherapy against sarcomas. 92
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells 91
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. 88
Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease 88
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective 88
INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES 86
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation 83
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidences and perspectives 79
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD 77
Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. 77
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 75
Cytokine profiling of end stage cancer patients treated with immunotherapy 74
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 74
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour 73
Cytokine-Induced Killer (CIK) Cells from Colorectal Cancer Patients after Nonmyeloablative Hematopoietic Cell Transplantation: Tumor Killing Capacity and Alloreactivity across MHC Barriers 73
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. 70
Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study 68
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 67
Alloreactivity and antitumor activity segregate within two distinct subsets of Cytokine-Induced Killer Cells: Implications for their infusion Across major HLA-barriers. 67
Veliparib: a new therapeutic option in ovarian cancer? 67
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 66
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 62
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 60
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. 59
Delving into PARP inhibition from bench to bedside and back 58
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 57
Sequential Lentiviral Transduction Conferring Simultaneous Sensitivity to Ganciclovir and Resistance to Mycophenolate Mofetil 55
Outcome of allogeneic hematopoietic cell transplantation (HCT) for patients with severe aplastic anemkia (SAA) above the age of 40 years 51
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 49
Role of interferon in melanoma: old hopes and new perspectives 49
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 47
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages 46
Treating breast cancer with cell-based approaches: an overview 46
Oncoretroviral and Lentiviral Transduction of Donor T Cells to Facilitate Engraftment of Dog Leukocyte Antigen (DLA)-Haploidentical T-Cell-Depleted Marrow 46
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 45
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 43
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers 42
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma 39
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19 37
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. 36
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 34
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect 34
Redirecting GVT after Allografting in Colorectal Cancer: Active Vaccination and Adoptive Immunotherapy 33
Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study 32
PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade 30
Redirectedt cells in cancer therapy 27
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective 25
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade 24
Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection 22
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets 22
MET Oncogene Targeting for Cancer Immunotherapy 21
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model 20
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 20
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis 19
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy 17
Cytokine induced killer cells as promising immunotherapy for solid tumors 16
Significance of TIM3 expression in cancer: From biology to the clinic 16
Predictive and dynamic signature for anti-angiogenics in combination with PD-1 inhibitor in soft-tissue sarcoma: correlative studies linked to the IMMUNOSARC trial 8
Totale 12.116
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.241
article - articoli 0
book - libri 0
conference - conferenze 3.161
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.402
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020533 0 0 0 0 0 0 0 0 161 158 98 116
2020/20211.305 84 125 89 114 98 86 76 80 110 132 110 201
2021/20221.235 69 91 48 74 73 47 86 74 60 111 279 223
2022/20231.779 126 171 42 174 129 400 148 127 216 53 123 70
2023/20241.074 109 158 74 84 62 161 56 59 11 75 101 124
2024/20251.562 57 161 156 223 462 204 90 163 46 0 0 0
Totale 12.116